Background Carvedilol, an antihypertensive agent with blocking and vasodilating properties, has been demonstrated to be effective in reducing blood pressure. The purpose of this study is to compare the antihypertensive efficacy, safety and tolerability of carvedilol and atenolol in patients with stage 1 to 2 essential hypertension.
confidence interval 17.8 11.6 with 50mg carvedilol and 13.6mmHg 95% confidence interval 17.3 9.9 with 100mg atenolol. There were no statistically significant differences between the two treatments in the percentage of patients achieving a normalized blood pressure or in the degree of change in mean peak sitting diastolic blood pressure. Safety profiles were similar between treatments. One patient withdrew due to severe bradycardia development during the second week of treatment with atenolol.
Conclusion In patients with mild to moderate hypertension, there were no significant differences between the efficacy of carvedilol or atenolol with regard to antihypertensive effect. Both carvedilol and atenolol were well tolerated with similar safety profiles. SiSBP：peak sitting systolic blood pressure HR：heart rate p-value 1) ：Significance of mean change in peak BP and HR by repeated measure ANOVA p-value 2) ：Significance of mean chnage in peak BP and HR(week 4-Baseline) by paired t-test p-value 3) ：Significance of mean chnage in peak BP and HR(week 8-Baseline) by paired t-test p-value 4) ：Significance between treatment by ANCOVA 72.9 8.5 62.9 8.3 -9.9 10.4 (-13.9 -5.9) NS NS：Not Significant ** p 0.01 p-value 1) ：Significance of mean change in peak BP or HR week 8-Baseline by paired t-test p-value 2) ：Significance between treatment by ANCOVA 11：247-256, 1997 
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